Elsevier

Clinical Neurophysiology

Volume 113, Issue 1, January 2002, Pages 141-150
Clinical Neurophysiology

Do high or low doses of anxiolytics and hypnotics affect mismatch negativity in schizophrenic subjects? An EEG and MEG study

https://doi.org/10.1016/S1388-2457(01)00710-6Get rights and content

Abstract

Objective: Many studies have demonstrated mismatch negativity (MMN) attenuation in schizophrenia. Recently, investigators have shown that GABAergic inhibitory neurons may regulate MMN generation. Considering that a substantial proportion of schizophrenic patients receive anxiolytics and hypnotics that have affinity to GABAA receptors to reduce their comorbid symptoms of anxiety and sleep disturbances, we need to assess whether anxiolytics/hypnotics might affect their MMN generation. The aim of this study is to assess the possibility that high or low doses of anxiolytics/hypnotics received by schizophrenic subjects affect their mismatch negativity (MMN), using event-related potentials (ERPs) and magnetoencephalography (MEG).

Methods: Twenty-three and 16 patients with schizophrenia participated in the ERP and MEG studies, respectively. Three types of MMN (MMN in response to a duration change of pure-tone stimuli, within-category vowel change (Japanese vowel /a/ with short versus long duration), and across-category vowel change (vowel /a/ versus /o/)) were recorded.

Results: High or low doses of benzodiazepine had no significant effects on MMN amplitude/magnetic MMN power, topography/laterality, or latency under any conditions of the ERP or MEG study.

Conclusions: These results suggest that chronic administration of anxiolytics/hypnotics does not significantly affect MMN in schizophrenia.

Introduction

Since the early clinical description by Bleuler (1911), it has been recognized that attentional deficits are one of the primary dysfunctions in schizophrenic psychopathology. The advent of event-related brain potential (ERP) studies has enabled an electrophysiological assessment of attentional dysfunction in schizophrenia. Earlier investigations focused on the evaluation of conscious, controlled aspects of attention in schizophrenia, and thus abnormalities of P300 (Roth et al., 1981, Kutcher et al., 1987, McCarley et al., 1989), N2b (Brecher et al., 1987), and the processing negativity (Michie et al., 1990) component of ERPs have been repeatedly reported. However, in 1991 Shelley et al. (1991) reported on impaired mismatch negativity (MMN) in response to a duration change of tones, an ERP index of auditory preattentive processing (Näätänen et al., 1978) in schizophrenia. Subsequent studies have replicated a reduction in MMN amplitude in response to a duration (Catts et al., 1995, Kasai et al., 1999c, Javitt et al., 2000b, Michie et al., 2000, Todd et al., 2000) and frequency (Javitt et al., 1993, Javitt et al., 1995, Javitt et al., 1998, Javitt et al., 2000a, Javitt et al., 2000b, Shutara et al., 1996, Alain et al., 1998, Hirayasu et al., 1998, Umbricht et al., 1998, Shelley et al., 1999) changes of tones in schizophrenia, although others did not find a significant reduction in the MMN in response to a frequency change of tones (O'Donnell et al., 1994, Kathmann et al., 1995, Oades et al., 1996, Kirino and Inoue, 1999). Recently, magnetoencephalography (MEG) (Kreitschmann-Andermahr et al., 1999) and functional magnetic resonance imaging (Wible et al., 2001) investigations have also demonstrated abnormalities of auditory mismatch detection in response to frequency changes of tones in schizophrenia.

Regarding the effects of psychotropic drugs on the MMN in schizophrenia, several reports have described no significant correlation between reported MMN amplitudes and the dose of neuroleptics administered to patients with chronic schizophrenia (Shelley et al., 1991, Shutara et al., 1996, Kasai et al., 1999c, Michie et al., 2000, Todd et al., 2000). Catts et al. (1995) and Javitt et al. (1995) independently found no significant difference in MMN amplitude between medicated and neuroleptic-free patients. Umbricht et al., 1998, Umbricht et al., 1999 showed that MMN reduction was not ameliorated by either typical (haloperidol) or atypical (clozapine or risperidone) medication. These reports provide a consensus that neuroleptics have no effect on MMN amplitude in schizophrenia. On the other hand, there is evidence from primate and human studies indicating that the interplay between excitatory glutamatergic and inhibitory GABAergic neurons regulates MMN generation (Javitt et al., 1996, Umbricht et al., 2000). Supporting this hypothesis, Nakagome et al. (1998) reported MMN amplitude reduction in the morning following administration of triazolam in normal subjects. Furthermore, Smolnik et al. (1998) observed a tendency towards an increase in MMN amplitude after the administration of the benzodiazepine antagonist, flumazenil, in normal subjects although the effect was not statistically significant. Considering that a substantial proportion of patients with schizophrenia receive anxiolytics and hypnotics to reduce the comorbid symptoms of anxiety and sleep disturbances, respectively (Carpenter et al., 1999, Hardy et al., 1999, Ito et al., 1999, Voirol et al., 1999), and that these drugs have affinity to GABAA receptors (Schroder et al., 1997, Fujita et al., 1999), we need to assess the possibility that anxiolytics/hypnotics might have some effect on MMN amplitude in schizophrenic patients. However, to our knowledge, only one preliminary study from our group (Murakami et al., 2001) has evaluated the possible effects of anxiolytics/hypnotics on the MMN in schizophrenic patients. Using a 16-channel montage, Murakami et al. compared the MMN and N2b in response to pure-tone stimuli between two subgroups of schizophrenic patients, one comprised of patients who did not receive benzodiazepines (benzodiazepine-off group; n=7) and the other of those who were administered benzodiazepines during daytime (benzodiazepine-on group; n=7). They found no significant differences in MMN and N2b amplitudes between the two subgroups, whereas the N2b latency was significantly prolonged in the benzodiazepine-on group relative to the benzodiazepine-off group. These results suggested that benzodiazepine had no marked effects on the MMN amplitude/latency in schizophrenia. The present study is an extension of our preliminary study; here, we determine whether the dose of anxiolytics/hypnotics affects MMN (or its magnetic counterpart, MMNm) amplitude (or MMNm power)/latency/topography (or laterality) in response to pure-tone and speech sounds in two new groups of patients with schizophrenia, using ERP and MEG recordings, respectively.

Section snippets

Subjects

Twenty-three right-handed (determined using the Edinburgh Inventory (Oldfield, 1971); we used a laterality index ≥0.8 as the cutoff for right-handedness), medicated outpatients with schizophrenia participated in this part of the study. Sixteen were male and 7 were female. This study is a post hoc analysis of our previous study comparing MMN between these 23 schizophrenic patients and 28 healthy subjects (Kasai et al., 2001a). Diagnosis was determined according to DSM-IV criteria (American

Results of ERP recording

The repeated measures ANOVA of MMN amplitude showed no significant main effects of group or interactions between group and any other factors: the main effect of group, F(1,21)=0.953, not significant (n.s.); group-by-condition interaction, F(2,42)=1.17, n.s.; group-by-hemisphere interaction, F(1,21)=0.042, n.s.; group-by-channel interaction, F(21,441)=0.577, n.s.; group-by-condition-by-hemisphere interaction, F(2,42)=0.342, n.s.; group-by-condition-by-channel interaction, F(42,882)=1.10, n.s.;

Discussion

The results of this study can be summarized as follows. (1) There were no differences in MMN amplitude (MMNm power), latency, effect of type of stimuli (nonverbal, verbal), or topography (laterality) between schizophrenic patients who received high and low doses of anxiolytics/hypnotics. (2) There were no significant correlations between MMN amplitude (MMNm power) or latency and dose of anxiolytics/hypnotics. Our results support our preliminary finding that there is no effect of benzodiazepines

Acknowledgements

This study was supported in part by a grant-in-aid for Scientific Research (No. 11680836) from the Japan Society for the Promotion of Science and a grant-in-aid for Scientific Research (C12670928) from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and by grants from the Welfide Medicinal Research Foundation, Japan and from the Uehara Memorial Foundation, Japan. The authors also gratefully acknowledge the technical support of Dr. S.F. Huang, and the administrative

References (65)

  • D. Lehmann et al.

    Spatial analysis of evoked potentials in man: a review

    Prog Neurobiol

    (1984)
  • A. Liasis et al.

    Intracranial identification of an electric frontal-cortex response to auditory stimulus change: a case study

    Brain Res Cogn Brain Res

    (2001)
  • P.T. Michie et al.

    Duration and frequency mismatch negativity in schizophrenia

    Clin Neurophysiol

    (2000)
  • R. Näätänen et al.

    Early selective-attention effect on evoked potential reinterpreted

    Acta Psychol

    (1978)
  • R.D. Oades et al.

    Auditory event-related potential (ERP) and difference-wave topography in schizophrenia patients with/without active hallucinations and delusions: a comparison with young obsessive-compulsive disorder (OCD) and healthy subjects

    Int J Psychophysiol

    (1996)
  • B.F. O'Donnell et al.

    Auditory ERPs to non-target stimuli in schizophrenia: relationship to probability, task demands, and target ERPs

    Int J Psychophysiol

    (1994)
  • R.C. Oldfield

    The assessment and analysis of handedness: the Edinburgh inventory

    Neuropsychologia

    (1971)
  • R.D. Pascual-Marqui et al.

    Low resolution electromagnetic tomography: a new method for localizing electrical activity in the brain

    Int J Psychophysiol

    (1994)
  • T. Rinne et al.

    Separate time behaviors of the temporal and frontal mismatch negativity sources

    Neuroimage

    (2000)
  • T. Rosburg et al.

    Habituation of the auditory evoked field component N100m in male patients with schizophrenia

    J Psychiatr Res

    (2000)
  • W.T. Roth et al.

    Auditory event-related potentials in schizophrenia and depression

    Psychiatry Res

    (1981)
  • J. Schroder et al.

    Benzodiazepine receptor distribution and diazepam binding in schizophrenia: an exploratory study

    Psychiatry Res

    (1997)
  • A-M. Shelley et al.

    Mismatch negativity: an index of a preattentive processing deficit in schizophrenia

    Biol Psychiatry

    (1991)
  • A-M. Shelley et al.

    Diminished responsiveness of ERPs in schizophrenic subjects to changes in auditory stimulation parameters: implications for theories of cortical dysfunction

    Schizophr Res

    (1999)
  • J. Todd et al.

    Auditory sensory memory in schizophrenia: inadequate trace formation?

    Psychiatry Res

    (2000)
  • D. Umbricht et al.

    Effects of clozapine on auditory event-related potentials in schizophrenia

    Biol Psychiatry

    (1998)
  • K. Alho et al.

    Processing of novel sounds and frequency changes in the human auditory cortex: magnetoencephalographic recordings

    Psychophysiology

    (1998)
  • DSM-IV: Diagnostic and statistical manual of mental disorders

    (1994)
  • E. Bleuler

    Dementia praecox or the group of schizophrenias

    (1911)
  • M. Brecher et al.

    The N2 component of the event-related potential in schizophrenic patients

    Electroenceph clin Neurophysiol

    (1987)
  • W.R. Carpenter et al.

    Diazepam treatment of early signs of exacerbation in schizophrenia

    Am J Psychiatry

    (1999)
  • S.V. Catts et al.

    Brain potential evidence for an auditory sensory memory deficit in schizophrenia

    Am J Psychiatry

    (1995)
  • Cited by (55)

    • Mismatch negativity (MMN) deficiency: A break-through biomarker in predicting psychosis onset

      2015, International Journal of Psychophysiology
      Citation Excerpt :

      An adequate NMDA-receptor function is a critical element in memory-trace formation at different hierarchical levels of the environmental representations and, hence, a central prerequisite of intact cognitive functioning (Baldeweg and Hirsch, 2014; Näätänen et al., 2011, 2014). Furthermore, the MMN can also be used for testing the treatment response in clinical trials (Baldeweg et al., 2006; Higuchi et al., 2010; Kasai et al., 2002; Fisher et al., 2012a; Inami et al., 2005) and as a tool of translational animal research for testing and developing animal models of psychosis and pharmacological agents (Nakamura et al., 2011; Gil-da-Costa et al., 2013; Ehrlichman et al., 2009; Javitt et al., 1994, 1996, 2012; Astikainen et al., 2011; see also Csépe et al., 1987; Kraus et al., 1994; for reviews, see Nagai et al., 2013; Todd et al., 2013). In conclusion, this review has shown that MMN deficiency at least in clinically at-risk individuals indexes a greatly increased psychosis risk and, in psychosis itself, a core aspect of it, viz., decreased brain plasticity and associated cognitive and functional decline.

    • Risky alcohol use predicts temporal mismatch negativity impairments in young people with bipolar disorder

      2014, Biological Psychology
      Citation Excerpt :

      Jahshan et al. (2012) has evaluated lithium in BD and found no effect on MMN. Previous studies have found no effect of benzodiazepines on MMN in schizophrenia (Kasai, Yamada, et al., 2002; Murakami et al., 2002), but this has not been investigated in BD. Antidepressants have been shown to have inconsistent effects, with research suggesting a broad range of serotonergic activity affects MMN (Wienberg, Glenthoj, Jensen, & Oranje, 2010), but this has not been specifically investigated in relation to BD.

    • Auditory mismatch negativity and P3a in response to duration and frequency changes in the early stages of psychosis

      2013, Schizophrenia Research
      Citation Excerpt :

      Third, MMN provides accurate characterization of sensory network dysfunction. This is important since medication, attention, and motivation have little effect on MMN (Catts et al., 1995; Michie et al., 2000; Michie, 2001; Kasai et al., 2002; Rissling et al., 2012). Fourth, MMN has a distributed neural architecture and therefore serves as a reliable probe of auditory network dysfunction (Takahashi et al., 2012).

    View all citing articles on Scopus
    View full text